×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

DiabetesIndia 2022: SGLT2 Inhibitor is 2nd Add-on for Everyone

  524 Views

Dr Piyush Desai, Surat    08 July 2022

  • Over the last 5 years, several landmark trials such as EMPA-REG, CANVAS, CREDENCE, DAPA HF and KDIGO have shown the multidimensional action of SGLT2 inhibitors in diabetes therapy and reducing the risk of CV renal outcomes.
  • Based on this evidence, ADA and AACE guidelines have been changed and recommend early prescription of SGLT2 inhibitors for patients with a high risk of ASCVD, CKD, HF, etc.
  • According to AACE guidelines, SGLT2 inhibitors can be used in combination with metformin, if the entry-level HbA1c is high.
  • SGLT2 inhibitor is a cost-effective drug that when reduces weight and the risk of hypoglycemia along with controlling several other risk factors.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.